Separately, HC Wainwright started coverage on Celsion in a research report on Tuesday, May 17th. They issued a “buy” rating and a $16.00 price target for the company.
Shares of CLSN stock opened at $1.92 on Wednesday. Celsion has a 52-week low of $1.80 and a 52-week high of $20.25. The company has a current ratio of 6.60, a quick ratio of 6.60 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $2.64 and a two-hundred day simple moving average of $5.22.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in shares of Celsion during the fourth quarter valued at approximately $55,000. GSA Capital Partners LLP raised its stake in Celsion by 435.2% in the fourth quarter. GSA Capital Partners LLP now owns 133,006 shares of the biotechnology company’s stock worth $72,000 after buying an additional 108,155 shares in the last quarter. Renaissance Technologies LLC bought a new position in Celsion in the fourth quarter worth approximately $59,000. FNY Investment Advisers LLC bought a new position in Celsion in the fourth quarter worth approximately $35,000. Finally, Jane Street Group LLC raised its stake in Celsion by 181.8% in the third quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock worth $33,000 after buying an additional 23,261 shares in the last quarter.
Celsion Company Profile (Get Rating)
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
- Get a free copy of the StockNews.com research report on Celsion (CLSN)
- Should Silver Stocks Be A Part Of Your Portfolio?
- This Still Isn’t A Buyable Bottom For Stocks
- ABM Industries, A Clean Play For Dirty Economic Times
- Don’t Get Too Bullish On Lennar Even Though It’s A Good Buy
- Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.